Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis
| Autor: | Bill Hulme, Dinesh Saralaya, Daniel Peckham, Miles Denton, Steve Conway, Caroline M Tobin, Christine Etherington |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Cystic Fibrosis medicine.drug_class Antibiotics medicine.disease_cause Gastroenterology Cystic fibrosis chemistry.chemical_compound Oral administration Internal medicine Acetamides medicine Humans Pharmacology (medical) Prospective Studies Dosing Oxazolidinones Antibacterial agent Pharmacology business.industry Linezolid Sputum Pancreatic Diseases biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Anti-Bacterial Agents Surgery Infectious Diseases chemistry Staphylococcus aureus Female medicine.symptom business |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 53:325-328 |
| ISSN: | 1460-2091 |
| DOI: | 10.1093/jac/dkh072 |
| Popis: | Objectives Linezolid is a new oxazolidinone antibiotic with efficacy against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In this study, we have determined the serum and sputum linezolid concentrations in adults with cystic fibrosis (CF) following oral drug administration. Methods Eleven adult patients with CF were recruited. Subjects received 600 mg of linezolid orally every 12 h for a total of six doses. Serum and sputum levels were measured just before and at 2 h after the final dose of linezolid. A further serum level was measured at 4 h. Results Ten adult patients completed the study. Mean (s.d.) serum linezolid concentrations were 2.3 mg/L (1.5) at 12 h following the fifth dose. At 2 and 4 h following the sixth dose, concentrations were 13.5 (4.3) and 8.1 (3.3). Mean (s.d.) linezolid sputum concentrations were 3.6 (2.1) and 17.4 (7.2) mg/L at 0 and 2 h following drug administration. Conclusions The oral administration of linezolid results in good sputum penetration in patients with CF. Mean levels exceed the required MIC for the treatment of MRSA for >80% of the dosing period for serum and the majority of the dosing period for sputum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|